Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Warranties And Reimbursements For Family Caregivers Provide Alternative Payment Methods
The New York Times reports on a proposal for a new health care reimbursement model that offers warranties to patients, a topic also examined in a piece by Francois de Brantes in the journal, Health Affairs. Brantes and co-authors developed a model, called the Prometheus Payment, which offers set fees to providers that "cover all recommended services, treatments and procedures for specific conditions but are also "risk-adjusted" for patients who may be older or frail. The warranty is based on the costs incurred by avoidable complications. In current fee-for-service plans, all costs from these complications are covered by the third party payer, regardless. But in the Prometheus Payment model, half of the costs from avoidable complications must be paid for by the providers themselves. The result, Mr. de Brantes and his co-authors write, is a payment system that offers patients a health care warranty, since "providers win or lose financially based on their actual performance in reducing the incidence of avoidable complications.""
generic viagra online
Potential Key To Maintaining Embryonic Stem Cells In Lab
In a new study that could transform embryonic stem cell (ES cell) research, scientists at UT Southwestern Medical Center have discovered why mouse ES cells can be easily grown in a laboratory while other mammalian ES cells are difficult, if not impossible, to maintain.
News of the day
Opinion: U.S. Global HIV/AIDS Funding; Maternal Health; Meeting Needs Of Recipient Nations
U.S. Lawmakers Should Not Slow AIDS Funding
Public Health

AIMSPRO Is Awarded TGA Orphan Status For The Treatment Of Amyotrophic Lateral Sclerosis

Privately owned UK biotech company Daval International Limited has been informed by Australia"s Therapeutic Goods Administration (TGA) that its innovative anti-inflammatory agent AIMSPRO(R) has been awarded Orphan Status for the treatment of Amyotrophic Lateral Sclerosis (ALS). ALS is the most common form of Motor Neuron Disease (MND), also known as Lou Gehrig"s disease. AIMSPRO has already achieved TGA Orphan Status for the treatment of Krabbe Leukodystrophy (Krabbe"s disease). Daval is now evaluating an international, multi-centre, placebo controlled, Randomised Clinical Trial to determine whether later stage ALS patients with poor respiratory function can be seen to benefit from the medication under double-blind conditions. AIMSPRO is a new generation biological medicine which is d and manufactured in Australia. It is derived from hyperimmune caprine serum and is currently under Phase II trialling in Europe for advanced Scleroderma and for bladder dysfunction in Secondary Progressive Multiple Sclerosis. Both trials are expected to report in the first quarter of 2010. Additional open label experience with AIMSPRO, over an extended period, has led Daval to consider Proof of Concept studies in Adhesive Arachnoiditis, treatment resistant Myasthenia Gravis and Psoriatic arthritis. AIMSPRO is listed on the Export Only section of the Australian Therapeutic Goods Registry and is imported into Europe by Biotec Distribution (Wales) Limited for clinical trial and "named patient use" purposes. The veterinary form of the product, Ceremben(R) has shown efficacy, safety and tolerability in studies addressing critically important indications in standardbred and thoroughbred horses. The Australian regulator, the APVMA, has recently awarded Ceremben a Research Permit, which will enable confirmatory equine field trials to be rapidly completed. Ceremben is also being developed as a potential canine and feline anti-inflammatory agent. Daval International Ltd


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009